Oramed Pharmaceuticals Analyst Ratings
Oramed Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/17/2023 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 01/12/2023 | — | Canaccord Genuity | Downgrades | Buy → Hold | |
| 05/16/2022 | 1233.33% | Aegis Capital | $35 → $30 | Maintains | Buy |
| 02/18/2022 | 788.89% | Cantor Fitzgerald | → $20 | Initiates Coverage On | → Overweight |
| 11/30/2021 | 1322.22% | HC Wainwright & Co. | $17 → $32 | Maintains | Buy |
| 11/29/2021 | 1322.22% | HC Wainwright & Co. | $17 → $32 | Maintains | Buy |
| 11/02/2021 | 1455.56% | Aegis Capital | $20 → $35 | Maintains | Buy |
| 07/29/2021 | 1233.33% | Canaccord Genuity | $27 → $30 | Maintains | Buy |
| 06/08/2021 | 788.89% | Aegis Capital | $12 → $20 | Maintains | Buy |
| 04/20/2021 | 1100% | Canaccord Genuity | → $27 | Initiates Coverage On | → Buy |
| 02/09/2021 | 922.22% | National Securities Corporation | → $23 | Initiates Coverage On | → Buy |
| 01/27/2021 | 433.33% | Aegis Capital | $6 → $12 | Maintains | Buy |
| 07/13/2020 | 655.56% | HC Wainwright & Co. | $16 → $17 | Reiterates | → Buy |
| 06/22/2020 | 611.11% | HC Wainwright & Co. | $20 → $16 | Maintains | Buy |
| 09/11/2019 | 211.11% | Ladenburg Thalmann | → $7 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 01/17/2023 | — | HC Wainwright公司 | 評級下調 | 購買→中性 | |
| 01/12/2023 | — | 卡納科特·格納奇 | 評級下調 | 購買→Hold | |
| 05/16/2022 | 1233.33% | 宙斯盾資本 | $35 → $30 | 維護 | 買 |
| 02/18/2022 | 788.89% | 康託·菲茨傑拉德 | → $20 | 開始承保 | →超重 |
| 11/30/2021 | 1322.22% | HC Wainwright公司 | $17 → $32 | 維護 | 買 |
| 11/29/2021 | 1322.22% | HC Wainwright公司 | $17 → $32 | 維護 | 買 |
| 11/02/2021 | 1455.56% | 宙斯盾資本 | $20 → $35 | 維護 | 買 |
| 07/29/2021 | 1233.33% | 卡納科特·格納奇 | $27 → $30 | 維護 | 買 |
| 06/08/2021 | 788.89% | 宙斯盾資本 | $12 → $20 | 維護 | 買 |
| 04/20/2021 | 1100% | 卡納科特·格納奇 | → $27 | 開始承保 | →購買 |
| 02/09/2021 | 922.22% | 國家證券公司 | → $23 | 開始承保 | →購買 |
| 01/27/2021 | 433.33% | 宙斯盾資本 | $6 → $12 | 維護 | 買 |
| 07/13/2020 | 655.56% | HC Wainwright公司 | $16 → $17 | 重申 | →購買 |
| 06/22/2020 | 611.11% | HC Wainwright公司 | $20 → $16 | 維護 | 買 |
| 09/11/2019 | 211.11% | 拉登堡·塔爾曼 | → $7 | 開始承保 | →購買 |
What is the target price for Oramed Pharmaceuticals (ORMP)?
Oramed PharmPharmticals(ORMP)的目標價是多少？
The latest price target for Oramed Pharmaceuticals (NASDAQ: ORMP) was reported by HC Wainwright & Co. on January 17, 2023. The analyst firm set a price target for $0.00 expecting ORMP to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.
奧萊德製藥(納斯達克：ORMP)的最新目標價是由HC Wainwright&Co.於2023年1月17日報道的。這家分析公司將目標價定為0.00美元，預計ORMP將在12個月內降至(可能-100.00%的跌幅)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Oramed Pharmaceuticals (ORMP)?
Oramed PharmPharmticals(ORMP)的最新分析師評級是多少？
The latest analyst rating for Oramed Pharmaceuticals (NASDAQ: ORMP) was provided by HC Wainwright & Co., and Oramed Pharmaceuticals downgraded their neutral rating.
分析師對奧萊德製藥(納斯達克代碼：ORMP)的最新評級由HC Wainwright&Co.提供，奧萊德製藥下調其中性評級。
When is the next analyst rating going to be posted or updated for Oramed Pharmaceuticals (ORMP)?
Oramed PharmPharmticals(ORMP)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oramed Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oramed Pharmaceuticals was filed on January 17, 2023 so you should expect the next rating to be made available sometime around January 17, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閲公共財務報表，與Oramed製藥公司的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Oramed製藥的上一次評級是在2023年1月17日提交的，所以你應該預計下一次評級將在2024年1月17日左右的某個時候公佈。
Is the Analyst Rating Oramed Pharmaceuticals (ORMP) correct?
分析師對Oramed PharmPharmticals(ORMP)的評級正確嗎？
While ratings are subjective and will change, the latest Oramed Pharmaceuticals (ORMP) rating was a downgraded with a price target of $0.00 to $0.00. The current price Oramed Pharmaceuticals (ORMP) is trading at is $2.25, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但Oramed PharmPharmticals(ORMP)的最新評級被下調，目標價為0.00美元至0.00美元。Oramed PharmPharmticals(ORMP)目前的交易價格為2.25美元，超出了分析師的預測區間。